Thus, patients were stratified into 3 new risk groups: (1) a high-risk group (bpHR) including MDD-positive patients and SC/LH morphological pattern (35/154 patients, 23%); (2) a low-risk group (bpLR) including MDD-negative patients without SC/LH pattern (45/154 patients, 29%); (3) an intermediate-risk group (bpIR) including all other patients with one of the two factors (74/154 patients, 48%). Here, PLOD1 is linked to major depressive disorder.